MRC1 and neoplasm: We used PU-WS13, a cell-permeable 6-amino-purine-based selective inhibitor of GRP94, to treat 4T1 tumor-bearing mice and showed, using SPECT/CT with 99mTc-Tilmanocept, a significant decrease in CD206+ M2-like macrophages after 11 days of treatment.